Lilly’s Retatrutide Outperforms Ozempic in Weight Loss and Blood Sugar Control Trial
In a late-stage diabetes study, retatrutide achieved 20.9% weight loss and a 2.2% reduction in A1C at 80 weeks, surpassing the results reported for
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 29 09:04 ETSource: Voice of Healthcare
From the source
Read at vohnetwork.comLilly’s Retatrutide Outperforms Ozempic in Weight Loss and Blood Sugar Control Trial
In a late-stage diabetes study, retatrutide achieved 20.9% weight loss and a 2.2% reduction in A1C at 80 weeks, surpassing the results reported for Ozempic.
